On November 9, 2022 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, reported that the company will participate in two upcoming investor conferences (Press release, Revolution Medicines, NOV 9, 2022, View Source [SID1234623652]). Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured speaker in fireside chats at the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference and the 5th Annual Evercore ISI HealthCONx Conference .
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of these events are as follows:
H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference
Conference Date: November 14, 2022
Fireside Chat Time/Date: 7:00 a.m. Eastern on Monday, November 14, 2022
Format: Virtual conference; webcast available
5th Annual Evercore ISI HealthCONx Conference
Conference Date: November 29 – December 1, 2022
Fireside Chat Time/Date: 2:15 p.m. Eastern on Thursday, December 1, 2022
Format: Virtual conference; webcast available
Webcasts of the H.C. Wainwright and Evercore ISI fireside chats can be accessed at: View Source Archived replays of the webcasts will be available on the investors section of the company’s website for at least 14 days following the events.